Portugal INFARMED

Jakavi (ruxolitinib) – Public funding evaluation report available; approval granted

Original title: Jakavi (ruxolitinib) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento

Portugal's INFARMED has approved public funding for Jakavi (ruxolitinib) following completion of the funding evaluation report.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement Portugal Reimbursement

Data : 21/08/2026

Dates and deadlines

Applies from

2026-08-21

Regulatory Deadline

August 21, 2026

Read the official source ↗

Published by Portugal INFARMED. HealthSignal links to the original document; the summary above is extracted from the source text.